Foam sclerotherapy

Phlebologie

Volumn 37, Issue 4, 2008, Pages 211-220

  Morrison, Nick ^a,b  

^a Morrison Vein Institute   (United States)

^b NONE   (United States)

Author keywords

Foam sclerotherapy; Transcranial Doppler; Transthoracic echocardiography

Indexed keywords

POLIDOCANOL; SILICON; TETRADECYL SULFATE SODIUM;

ADVERSE OUTCOME; ARTICLE; CHEST TIGHTNESS; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; COUGHING; DEEP VEIN THROMBOSIS; DIZZINESS; FEMORAL VEIN; FOLLOW UP; HEADACHE; HUMAN; INTRAVENOUS CATHETER; NAUSEA; NONHUMAN; PATIENT MONITORING; RISK ASSESSMENT; SCLEROTHERAPY; THORAX PAIN; ULTRASOUND; VEIN INSUFFICIENCY; VISUAL DISORDER;

EID: 53549120202     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1622233     Document Type: Article

References (54)

1. Orbach EJ. Contributions to the therapy of the varicose complex. J Int Coll Surg 1950; 29: 765-771.
2. Cabrera Garrido J, Cabrera JR J, Garcia-Olmedo MA. Elargissement des limites de la sclerotherapie: nouveaux produits sclerosants. Phlebologie 1997; 50: 181-188.
3. Monfreux A. Treatement sclerosant des troncs sapheneis et leurs collaterales e gros calibre par la methode MUS. Phlebologie 1997; 50: 351-353.
4. Tessari L. Nouvelle technique d'obtention de la sclero-mousse. Phlebologie 2000; 53: 129-133.
5. Cabrere AL. Endoluminal therapy with echo-guided sclerosing foam - Current situation after 30 years of experience. UIP World Congress Chapter Meeting, San Diego, California, 2003.
6. Hamel-Desnos C, Ouvry P, Benigni J-P, Boitelle G, Schadeck M, Desnos P, Allaert F-A. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: A randomised, double-blind trial with 2-year follow-up. "The 3/1 Study". Eur J Vasc Endovasc Surg 2007; 34: 723-729.
7. Yamaki T, Nozaki M, Iwasaka S. Comparative study of duplex-guided foam sclerotherapy and duplex-guided liquid sclerotherapy for the treatment of superficial venous insufficiency. Dermatol Surg 2004; 30: 718-722.
8. Hamel-Desnos C, Allaert FA, Benigni J, Boitelle G, Chleir F, Ouvry P et al. Polidocanol foam 3% versus 1% in the great saphenous vein: Early results. Phlebologie 2005; 58: 175-182.
9. Belcaro G, Cesarone MR, Di Renzo A, Brandolini R, Coen L, Acerbi G et al. Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: A 10-year, prospective, randomized, controlled, trial (VEDICO trial). Angiology 2003; 54: 307-315.
10. Cabrera J, Cabrera J Jr, Garcia-Olmedo A. Treatment of varicose long saphenous veins with micro-foam form: Long-term outcomes. Phlebology 2000; 15: 19-23.
11. McDonagh B, Huntley DE, Rosenfeld R, King T, Harry JL, Sorenson S et al. Efficacy of the comprehensive objective mapping, precise image guided injection, anti-reflux positioning and sequential sclerotherapy (COMPASS) technique in the management of greater saphenous varicosities with saphenofemoral incompetence. Phlebology 2002; 17: 19-28.
12. Grondin L. Foam echosclerotherapy of incompetent saphenous veins. Phlebolymphology 2003; 42: S24.
13. Morrison N. The Interaction and Complimentary Role of Surgery, Sclerotherapy and Thermal Ablation in the Managment of Varicose Veins - The US Perspective. The Australian and New Zealand Society for Vascular Surgery, Melbourne, August 2007.
14. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): A randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008; 35: 238-245.
15. Myers KA, Jolley D, Clough A, Kirwan J. Outcome of ultrasound-guided sclerotherapy for varicose veins: Medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 33: 116-121.
16. Wollmann JC. An Experimental Model to Pinpoint Properties and Behavior of Sclerosing Foams. 17th Annual Congress of the American College of Phlebology, San Diego, California, 2003.
17. th Annual Congress of the American College of Phlebology, Fort Lauderdale, Florida, 2002.
18. Morrison N. Large-volume, ultrasound-guided, polidocanol foam sclerotherapy: A prospective study of toxicity and complications. International Vein Congress 2004. Key Biscayne, Florida, 2004.
19. Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007; 94: 925-936.
20. Gobin JP. French experience with sclerotherapy. Angiologia E Cirurgia Vascular, Ubelandia, Brazil, 2008.
21. nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa 2008; 37: 90-95.
22. Frullini A, Cavezzi A. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications. Dermatol Surg 2002; 28: 11-15.
23. Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004; 30: 694-703.
24. Coleridge Smith P. Saphenous ablation: sclerosant or sclerofoam? Semin Vasc Surg 2005; 18: 19-24.
25. Fegan WG. Injection with compression as a treatment for varicose veins. Proc R Soc Med 1965; 58: 874-876.
26. Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. Dermatol Surg 2004; 30: 6-12.
27. Cabrera J, Redondo P, Becerra A, Garrido C, Cabrera J Jr, Garcia-Olmedo MA et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004; 140: 667-673.
28. Cavezzi A, Frullini A. The role of sclerosing foam in ultrasound guided sclerotherapy of the saphenous veins and of recurrent varicose veins: Our personal experience. Aust NZ J Phlebol 1999; 3: 49-50.
29. Kakkos SK, Bountouroglou DG, Azzam M, Kalodiki E, Daskalopoulos M, Geroulakos G.Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: Immediate results. J Endovasc Ther 2006; 13: 357-364.
30. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg 2004; 30: 367-372.
31. Rabe E, Pannier-Fischer F, Gerlach H, Breu FX, Guggenbichler S, Zabel M. Guidelines for sclerotherapy of varicose veins (ICD 10: 183.0, 183.1, 183.2, and 183.9). Dermatol Surg 2004; 30: 687-693.
32. Coleridge Smith P. Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006; 32: 577-583.
33. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27: 58-60.
34. Wright D, Gobin JP, Bradbury AW, Coleridge Smith P, Spoelstra H, Berridge D et al. Varisolve polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006; 21: 180-190.
35. Henriet JP. Expérience durant trois années de la mousse de polidocanol dans le traitement des varices réticulaires et des varicosities. Phlébologie 1999; 52: 277-282.
36. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: Report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123-128.
37. Hamel-Desnos C, Guias B, Jousse S, Desnos P, Bressollette L. Foam echosclerotherapy by puncture-direct injection: Technique and quantities. J Mal Vasc 2006; 31: 180-189.
38. O'Hare JL, Earashaw JJ. The use of foam sclerotherapy for varicose veins: A survey of the members of the Vascular Society of Great Britain and Ireland. Eur J Vas Endovasc Surg 2007; 34: 232-235.
39. Eckmann DM, Kobayashi S, Li M. Microvascular embolization following polidocanol microfoam sclerosant administration. Dermatol Surg 2005; 31: 636-643.
40. Hoffman K. An unusual complication of facial sclerotherapy. Dermatol Surg 2003; 29: 423-424.
41. th Annual Congress of the American College of Phlebology, Ft Lauderdale, Florida, 2002.
42. Scurr J, Gilling-Smith G, Fisher R. Letter to the editor: Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007; 94: 925-936. 1306-1309.
43. Alòs J, Carreño P, López JA, Estadella B, Serra-Prat M. Efficacy and safety of sclerotherapy using polidocanol foam: A controlled clinical trial. Eur J Vas Endovasc Surg 2006; 31: 101-107.
44. Brodersen J, Geismar U. Catheter-assisted vein sclerotherapy: A new approach for sclerotherapy of the greater saphenous vein with a double-lumen balloon catheter. Dermatol Surg 2007; 33: 469-475.
45. Neuhardt D. Incidence of deep vein thrombosis in a duplicated femoral vein following Foam USG of the GSV First Days of Phlebology, Parma, Italy. 2006.
46. Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison T, Johnson E, Salles-Cunha SX. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47: 830-836.
47. Lai SW, Goldman MP. Does the relative silicone content of different syringes affect the stability of foam in sclerotherapy? J Drugs Dermatol 2008; 7: 399-340.
48. Tessari L. 8° International Phlebological Symposium, Bologna, Italy, 2006.
49. st Annual Congress, American College of Phlebology, Tucson, Arizona, 2007.
50. Creton D, Uhl JF. Foam sclerotherapy combined with surgical treatment for recurrent varicose veins: Short term results. Eur J Vas Endovasc Surg 2007; 33: 619-624.
51. Pascarella L, Bergan JJ, Mekenas LV. Severe chronic venous insufficiency treated by foamed sclerotherapy. Ann Vasc Surg 2006; 20: 83-91.
52. Dona E, Fletcher JP, Hughes TM, Saker K, Batiste P, Ramanathan I. Duplicated popliteal and superficial femoral veins: incidence and potential significance. Aust N Z J Surg 2000; 70: 438-440.
53. Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107: 5-9.
54. Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April 4-6, 2003, Tegernsee, Germany. Dermatol Surg 2004; 30: 709-717.